



XOLAIR (OMALIZUMAB) Infusion Orders

PHONE 515.225.2930 | FAX 515.559.2495

Patient Information

Fax completed form, insurance information and clinical documentation to 515.559.2495.

Patient Name: _____ **DOB:** _____ **Phone:** _____

Patient Status: New to Therapy Continuing Therapy **Next Treatment Date:** _____

Medical Information

Diagnosis: Moderate to severe persistent asthma Polyp of the nasal cavity Allergic urticaria
Idiopathic urticaria Chronic obstructive pulmonary disease **ICD-10 Code:** _____

Patient Weight: _____ lbs. (required) **Allergies:** _____

Therapy Order

Xolair dose:
150 mg 225 mg 300 mg 375 mg 450 mg 525 mg 600 mg

Frequency: Subcutaneously every: 2 weeks x1 year OR 4 weeks x1 year

Note: Patient must have an EpiPen in their possession on their appointment date.*

Other Orders: _____

Lab Orders: _____ **Lab Frequency:** _____

Required labs to be drawn by: Infusion Center Referring Provider

Provider Information

By signing this form and utilizing our services, you are authorizing Hy-Vee Health and its employees to serve as your prior authorization and specialty pharmacy designated agent in dealing with medical and prescription insurance companies, and to select the preferred site of care for the patient.

Provider Name: _____ **Signature:** _____ **Date:** _____

Provider NPI: _____ **Phone:** _____ **Fax:** _____ **Contact Person:** _____

Opt out of Hy-Vee Health selecting site of care (if checked, please list site of care): _____

Service Areas

Des Moines, IA West Des Moines, IA Chicago, IL Omaha, NE Buffalo, NY Dallas, TX
Phoenix, AZ Other _____

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.



COMPREHENSIVE SUPPORT FOR XOLAIR (OMALIZUMAB) THERAPY

Patient Information

Patient Name: _____ DOB: _____

Required Documentation for Referral Processing & Insurance Approval

Include signed and completed order (MD/prescriber to complete page 1)

Include patient demographic information and insurance information

Include patient's current medication list

Supporting clinical notes to include any past tried and/or failed therapies, intolerance, benefits or contraindications to conventional therapy

Please indicate any tried and failed therapies (if applicable):

Corticosteroids _____

Long-acting beta 2 agonist _____

Long-acting muscarinic antagonist _____

Antihistamines: _____

Other: _____

Asthma – Does the patient have a history of 2 exacerbations requiring a course of oral/systemic corticosteroids, hospitalization or an emergency room visit within a 12-month period? Yes No

Asthma – Does the patient have an ACQ score consistently greater than 1.5 or ACT score consistently less than 120? Yes No

Nasal polyps – Does the patient have significant rhinosinusitis symptoms such as nasal obstruction, rhinorrhea or loss of smell? Yes No

Include labs and/or test results to support diagnosis

Asthma and Polyps – Does patient have a baseline IgE level of ≥ 30 IU/mL Yes No **(required – attach results)**

Does the patient have an allergy to a perennial aeroallergen? Yes No

(required for asthma patients – attach results)

Pulmonary function tests or FEV1 score (if applicable): _____

Is the patient or caregiver not competent or physically unable to administer Xolair for self-administration or patient is not home candidate? **(UHC only)** Yes No

Other Medical Necessity: _____

Hy-Vee Health will complete insurance verification and submit all required documentation for approval to the patient's insurance company for eligibility. Our team will notify you if any additional information is required. We will review financial responsibility with the patient and refer him/her to any available co-pay assistance as needed. Thank you for the referral.

HY-VEEHEALTHINFUSION.COM

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee and contains material that is confidential, privileged property or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately and destroy all copies if you have received this document in error.